ESR1 and breast carcinoma: Furthermore, two randomized trials that evaluated the administration of GnRHa during chemotherapy also in patients with estrogen receptor-positive breast cancer and its impact on survival showed no difference in the survival outcomes; in both studies, most of the patients were also treated with GnRHa as part of their adjuvant endocrine therapy [58,62].